Provided by Tiger Trade Technology Pte. Ltd.

FOSUN PHARMA

18.230
0.000
Volume:- -
Turnover:- -
Market Cap:48.47B
PE:15.48
High:18.230
Open:18.230
Low:18.230
Close:18.230
52wk High:29.000
52wk Low:12.535
Shares:2.66B
HK Float Shares:540.97M
Volume Ratio:- -
T/O Rate:- -
Dividend:0.35
Dividend Rate:1.92%
EPS(LYR):1.178
ROE:6.75%
ROA:1.32%
PB:0.89
PE(LYR):15.48
PS:1.08

Loading ...

FOSUN PHARMA (600196.SH): Supplemental New Drug Application for Serplulimab Injection Accepted

Stock News
·
Dec 12, 2025

FOSUN PHARMA (600196.SH): Ketoprofen Patch Receives Clinical Trial Approval

Stock News
·
Dec 12, 2025

Capital Securities Maintains "Buy" Rating on Fosun Pharma (02196) with Target Price of HK$26.5

Stock News
·
Dec 10, 2025

Pfizer Turns to China for Trial Weight Loss Drug. Congress Is Worried About Chinese Biotechs. -- Barrons.com

Dow Jones
·
Dec 10, 2025

FOSUN PHARMA (600196.SH): HLX22 Combined with HLX87 Injection Receives Clinical Trial Approval

Stock News
·
Dec 09, 2025

Fosun Pharma Subsidiary Yao Pharma Grants Pfizer Exclusive Global License for Oral GLP-1R Agonists

Reuters
·
Dec 09, 2025

Fosun Pharmaceutical Says Unit to Receive Upfront Payment of $150 Mln

THOMSON REUTERS
·
Dec 09, 2025

BRIEF-Fosun Pharmaceutical Says Unit Signs Licensing Agreement With Pfizer

Reuters
·
Dec 09, 2025

Fosun Pharma (600196.SH, 02196.HK) Gains Approval for Clinical Trial of FXS0887

Bulletin Express
·
Dec 03, 2025

FOSUN PHARMA (02196): Liu Yi Elected as Executive Director

Stock News
·
Dec 02, 2025

Fosun Pharma (02196.HK / 600196.SH) Releases November 2025 Monthly Return on Movements in Securities

Bulletin Express
·
Dec 02, 2025

Fosun Pharma's (600196.SH) Subsidiary Receives Clinical Trial Approval for HLX37 Injection

Stock News
·
Dec 01, 2025

Fosun Pharmaceutical's Routine Transaction Amounts to 132 Million Yuan in First Nine Months

MT Newswires Live
·
Dec 01, 2025

Fosun Pharma (02196.HK) Announces Three Continuing Connected Transactions with CQ Pharma (000950.SZ) and Fosun International (00656.HK)

Bulletin Express
·
Nov 28, 2025

Fosun Pharma Unit's Registration Application for Langerhans Cell Histiocytosis Drug Accepted in China

MT Newswires Live
·
Nov 21, 2025

FOSUN PHARMA's (600196.SH) Subsidiary Receives Acceptance for Luvo Mertinib Tablets Drug Registration Application

Stock News
·
Nov 21, 2025

Fosun Pharmaceutical's Serplulimab Injection Included in Chinese Drug Regulator's Breakthrough Therapy Drug Program; Shares Down 4%

MT Newswires Live
·
Nov 21, 2025

Fosun Pharma's HLX10 (Serplulimab) Included in Breakthrough Therapy Program for Gastric Cancer Treatment

Stock News
·
Nov 20, 2025

Analysis of Hong Kong Stock Connect Holdings as of November 19

Stock News
·
Nov 19, 2025

HKEX Announcement Highlights | XIAOMI-W Reports Record High Adjusted Net Profit of RMB11.311 Billion in Q3, Smartphone Shipments Grow YoY for 9 Consecutive Quarters

Stock News
·
Nov 18, 2025